Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $52.06, marking a +2.1% move from the previous day. This change outpaced the S&P 500's 0.49% loss on the day. Elsewhere, the Dow ...

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its ...

Non-model crop species represent a vast and diverse component of global agriculture, forestry, and horticulture, yet they are routinely underrepresented in ...

The cultivar is giving the industry renewed confidence in the future, said Florida Citrus Mutual Board President Kevin ...

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

Recent studies highlight how artificial intelligence and CRISPR-based molecular tools are reshaping gastrointestinal diagnostics, from intestinal tuberculosis to colon polyp detection. AI-assisted ...

CRISPR gene editing specialist Intellia Therapeutics has announced positive topline results from the global Phase III HAELO ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...